Understanding sex hormones and inflammation in heart disease
Official title: Barts Sex-CAD Database: Do Female Sex Hormone Levels Inform Inflammatory Status and Susceptibility in Women Suffering Coronary Artery Disease?
Run by Queen Mary University of London · NCT06327984 · Data updated 2026-11-12
This study looks at how sex hormones and inflammation affect heart disease in women to better understand their unique risks and improve treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 16 Years and up |
| Sex | All |
| Enrollment | 6000 (estimated) |
| Sponsor | Queen Mary University of London Academic / other |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | November 21, 2023 |
| Main results expected | January 31, 2033 |
| Study ends | January 31, 2033 |
| Registry record updated | September 9, 2026 |
| Trial ID | NCT06327984 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients aged 16 and older presenting with chest pain at Barts Heart Centre.
✕Probably not a fit
Patients under 16 years old or those lacking the capacity to participate will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the role of sex hormones and inflammatory markers in the progression of coronary artery disease (CAD), particularly in women. Researchers will collect data on hormone levels and various blood markers from patients admitted to Barts Heart Centre with chest pain. A questionnaire will also be administered to gather relevant medical history that may influence hormone status. The findings could help clarify the biological differences in CAD development between genders and improve patient care.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and treatment strategies for coronary artery disease in women.
How similar studies have gone: While there is limited research specifically addressing sex differences in CAD, studies exploring hormonal influences on cardiovascular health have shown promising insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria Any patient presenting with chest pain ≥16 years old presenting to Barts Heart Centre will be included. Exclusion criteria Patients \<16 years old and Adults lacking capacity will be excluded. Patients where the cause of their chest pain presentation is not related to coronary artery disease e.g musculoskeletal chest pain, aortic dissection, gastrointestinal, pulmonary embolism
Where it's running
-
Barts Health NHS Trust
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Krishnaraj Rathod, MBBS PhD — Queen Mary University of London
- Study coordinator: Krishnaraj Rathod, MBBS PhD
- Email: k.s.rathod@qmul.ac.uk
- Phone: 020 7882 5720
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Single versus dual antiplatelet therapy after drug-coated balloon angioplasty in elderly or high-bleeding-risk patients
This study tests whether taking one antiplatelet medicine is as safe and causes less bleeding than taking two medicines for people aged 75 or older, or adults at high bleeding risk, after drug-coated balloon angioplasty for coronary artery disease.
-
Investigating heart-related side effects of cancer immunotherapy
This study is testing whether cancer immunotherapy treatments can cause heart problems in patients with certain types of cancer.
-
Assessing heart disease risk using carotid ultrasound and stress tests
This study is testing if combining a special ultrasound of the neck with stress tests can better identify people at risk for serious heart problems over the next three years.
-
Registry collecting data on patients undergoing heart artery procedures
This study is collecting information from patients who are having heart artery procedures to see how they do during and after their treatment.
-
Optimal antithrombotic strategy for patients with atrial fibrillation undergoing PCI
This study is testing whether a new blood-thinning treatment for patients with atrial fibrillation undergoing heart procedures is safer and just as effective as the traditional approach that includes more medications.
-
Comparing a new medication to standard treatment for preventing stomach issues in heart patients on blood thinners
This study is testing a new medication called tegoprazan to see if it can prevent stomach problems just as well as the standard treatment for heart patients who are taking blood thinners.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.